A Phase 2 interventional study of Pegcetacoplan in PNH, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-22.
Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase IIa, open-label, multiple dose, study in patients with PNH who have not received eculizumab (Soliris ®) in the past. A single cohort of subjects is planned for evaluation.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
This study's enrollment of 4 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Browse Hemoglobinuria, Paroxysmal studies →Apellis Pharmaceuticals, Inc. is the lead sponsor of 28 studies on the registry; 3 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
270 mg/day (up to 360 mg/day from Day 29) from Day 1 to Day 364\*
Drug: Pegcetacoplan
Complement (C3) Inhibitor
Also known as: APL-2
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity
TEAEs were defined as adverse events (AE) that occurred after dosing on Day 1 and up to 30 days after the last dose of study drug. A treatment-related TEAE was defined as a TEAE with a relationship to study drug of possible, probable, or definite. TEAEs were graded according to the Common Terminology Criteria for Adverse Events (v4.03) based on: Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-threatening, Grade 5: Death related to AE.
Time frame: From Day 1 to 30 days after the last dose (approximately 56 weeks)
Mean Change From Baseline in Lactate Dehydrogenase (LDH) Level
Serum chemistry assessments of LDH were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.
Time frame: Baseline and Day 365
Mean Change From Baseline in Haptoglobin Level
Serum chemistry assessments of haptoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.
Time frame: Baseline and Day 365
Mean Change From Baseline in Hemoglobin (Hb) Level
Hematology assessments of Hb were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.
Time frame: Baseline and Day 365
Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score
The FACIT-Fatigue scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. Higher score corresponds to a higher quality of life (QoL).
Time frame: Baseline and Day 365
Mean Change From Baseline in Absolute Reticulocyte Count (ARC) Level
Hematology assessments of ARC were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.
Time frame: Baseline and Day 365
Mean Change From Baseline in Total Bilirubin Level
Serum chemistry assessments of total bilirubin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.
Time frame: Baseline and Day 365
Mean Number of Red Blood Cell (RBC) Transfusions Per Month
The number of on-study RBC transfusions was monitored throughout the treatment period.
Time frame: From Day 1 to Day 364
Mean Change From Baseline in Linear Analog Scale Assessment (LASA) Score for QoL
The LASA consists of 3 items, where the respondents were asked to rate their perceived level of functioning. Specific domains included activity level, ability to carry out daily activities, and an item for overall QoL. Their level of functioning was reported on a 0 to 100 scale with 0 indicates "As low as could be" and 100 indicates "As high as could be". The combined score ranged from 0 to 300, with higher scores corresponding to a higher QoL.
Time frame: Baseline and Day 365
Mean Serum Concentrations of Pegcetacoplan
Serum concentrations of pegcetacoplan at Day 365 are presented.
Time frame: Day 365
Mean Area Under the Serum Concentration Versus Time Curve From Time 0 to the Last Measurable Concentration at the End of the Study (AUCtotal)
The AUCtotal of pegcetacoplan was estimated using a non-compartmental approach.
Time frame: Blood samples were collected predose and at least 2.5 hours post dose on Day 1 and predose on Days 2 up to Day 365.
Mean Maximum Observed Predose Serum Concentration During the Study (Ctrough,Max,Total)
The Ctrough,max,total of pegcetacoplan was estimated using a non-compartmental approach.
Time frame: Blood samples were collected predose and at least 2.5 hours post dose on Day 1 and predose on Days 2 up to Day 365.
This Phase 2a, open-label, multiple-dose study was conducted in subjects with paroxysmal nocturnal hemoglobinuria (PNH) who had not received treatment with eculizumab (Soliris®) in the past, between 16 August 2018 and 22 October 2019.
| Milestone | Pegcetacoplan 270 mg/Day |
|---|---|
| Started | 4 |
| Completed | 4 |
| Not completed | 0 |
TEAEs were defined as adverse events (AE) that occurred after dosing on Day 1 and up to 30 days after the last dose of study drug. A treatment-related TEAE was defined as a TEAE with a relationship to study drug of possible, probable, or definite. TEAEs were graded according to the Common Terminology Criteria for Adverse Events (v4.03) based on: Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-threatening, Grade 5: Death related to AE.
| Participants | Pegcetacoplan 270 mg/Day |
|---|---|
| All TEAEs | 3 |
| Treatment-related TEAEs | 2 |
| Serious TEAEs | 1 |
| TEAEs leading to study drug discontinuation | 0 |
| TEAEs with mild intensity | 2 |
| TEAEs with moderate intensity | 0 |
| TEAEs with severe intensity | 1 |
| TEAEs with life threatening intensity | 0 |
| TEAEs leading to death | 0 |
Serum chemistry assessments of LDH were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.
| units/liter | Pegcetacoplan 270 mg/Day |
|---|---|
| Mean Change From Baseline in Lactate Dehydrogenase (LDH) Level | -2322.8 ± 635.41 |
Serum chemistry assessments of haptoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.
| grams/liter | Pegcetacoplan 270 mg/Day |
|---|---|
| Mean Change From Baseline in Haptoglobin Level | 0.08 ± 0.150 |
Hematology assessments of Hb were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.
| grams/deciliter | Pegcetacoplan 270 mg/Day |
|---|---|
| Mean Change From Baseline in Hemoglobin (Hb) Level | 5.27 ± 1.875 |
The FACIT-Fatigue scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. Higher score corresponds to a higher quality of life (QoL).
| score on a scale | Pegcetacoplan 270 mg/Day |
|---|---|
| Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score | 6.5 ± 5.45 |
Hematology assessments of ARC were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.
| ARC/nanoliter | Pegcetacoplan 270 mg/Day |
|---|---|
| Mean Change From Baseline in Absolute Reticulocyte Count (ARC) Level | -144.3 ± 98.51 |
Serum chemistry assessments of total bilirubin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.
| micromoles/liter | Pegcetacoplan 270 mg/Day |
|---|---|
| Mean Change From Baseline in Total Bilirubin Level | -21.53 ± 8.358 |
The number of on-study RBC transfusions was monitored throughout the treatment period.
| transfusions | Pegcetacoplan 270 mg/Day |
|---|---|
| Mean Number of Red Blood Cell (RBC) Transfusions Per Month | 0 (0 to 0) |
The LASA consists of 3 items, where the respondents were asked to rate their perceived level of functioning. Specific domains included activity level, ability to carry out daily activities, and an item for overall QoL. Their level of functioning was reported on a 0 to 100 scale with 0 indicates "As low as could be" and 100 indicates "As high as could be". The combined score ranged from 0 to 300, with higher scores corresponding to a higher QoL.
| score on a scale | Pegcetacoplan 270 mg/Day |
|---|---|
| Mean Change From Baseline in Linear Analog Scale Assessment (LASA) Score for QoL | 66.5 ± 55.75 |
Serum concentrations of pegcetacoplan at Day 365 are presented.
| microgram per milliliter (ug/mL) | Pegcetacoplan 270 mg/Day |
|---|---|
| Mean Serum Concentrations of Pegcetacoplan | 622.0 ± 92.13 |
The AUCtotal of pegcetacoplan was estimated using a non-compartmental approach.
| hour*ug/mL | Pegcetacoplan 270 mg/Day |
|---|---|
| Mean Area Under the Serum Concentration Versus Time Curve From Time 0 to the Last Measurable Concentration at the End of the Study (AUCtotal) | 5818803.2534 ± 975444.77662 |
The Ctrough,max,total of pegcetacoplan was estimated using a non-compartmental approach.
| ug/mL | Pegcetacoplan 270 mg/Day |
|---|---|
| Mean Maximum Observed Predose Serum Concentration During the Study (Ctrough,Max,Total) | 783.5 ± 116.25 |
Collected over TEAEs were collected from Day 1 up to 30 days after the last dose of study drug (a total of approximately 56 weeks).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pegcetacoplan 270 mg/Day | 0/4 (0%) | 1/4 (25%) | 3/4 (75%) |
| Event | Pegcetacoplan 270 mg/Day |
|---|---|
| Rib fractureInjury, poisoning and procedural complications | 1/4 |
| Event | Pegcetacoplan 270 mg/Day |
|---|---|
| DizzinessNervous system disorders | 2/4 |
| ErythemaSkin and subcutaneous tissue disorders | 2/4 |
| Administration site swellingGeneral disorders | 1/4 |
| Injection site discolourationGeneral disorders | 1/4 |
| Injection site erythemaGeneral disorders | 1/4 |
| Injection site pruritusGeneral disorders | 1/4 |
| Injection site swellingGeneral disorders | 1/4 |
| RhinitisInfections and infestations | 1/4 |
| Scrotal irritationReproductive system and breast disorders | 1/4 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/4 |
The safety set consisted of all subjects who received at least 1 dose of study drug.
| Age, Continuous(years) | Pegcetacoplan 270 mg/Day |
|---|---|
| Mean | 30.8 ± 11.81 |
| Sex: Female, Male(Participants) | Pegcetacoplan 270 mg/Day |
|---|---|
| Female | 3 |
| Male | 1 |
| Race/Ethnicity, Customized(Participants) | Pegcetacoplan 270 mg/Day |
|---|---|
| White | 4 |
| Not Hispanic or Latino | 4 |
| Region of Enrollment(participants) | Pegcetacoplan 270 mg/Day |
|---|---|
| Bulgaria | 2 |
| Serbia | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2018 to primary completion in Oct 2019, 14 months.
Results were first posted in Dec 2020, 1 year 2 months after primary completion.
Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's 14 months is below that.
Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegcetacoplan
Apellis Pharmaceuticals, Inc. →